Chronic Obstructive Pulmonary Disease Management

Patient Selection

• Roflumilast is recommended for patients with severe to very severe COPD (FEV1 <50% predicted) and a history of exacerbations despite optimal inhaled therapy, particularly those with chronic bronchitis phenotype, by the American Thoracic Society, European Respiratory Society, and GOLD guidelines 1, 2, 3, 4
• The medication is most appropriate for patients with severe to very severe airflow obstruction, chronic bronchitis phenotype, and a history of exacerbations despite optimal inhaled therapy, as recommended by the European Respiratory Society 2, 3, 4

Clinical Benefits

• Roflumilast reduces moderate and severe exacerbations (rate ratio 0.85, 95% CI 0.78-0.91) and decreases the proportion of patients experiencing exacerbations (21.4% versus 25.2%; risk ratio 0.85, 95% CI 0.78-0.94) in patients with severe COPD, according to the European Respiratory Society 2
• The treatment increases time to next exacerbation (hazard ratio 0.88, 95% CI 0.81-0.96) and improves lung function with increased post-bronchodilator FEV1 (mean difference +56.29 mL) in patients with severe COPD, as stated by the European Respiratory Society 2
• Roflumilast appears to be more effective in frequent exacerbators (≥2 exacerbations/year) (RR 0.78, 95% CI 0.66-0.91) 5

Adverse Effects

• Common adverse effects of Roflumilast include gastrointestinal effects (diarrhea, nausea), weight loss, psychiatric disorders (anxiety, depression), and sleep disturbance/insomnia, as reported by the European Respiratory Society 2
• The medication has a higher discontinuation rate due to adverse effects (14.9% vs 9.0%) compared to placebo, according to the European Respiratory Society guidelines 2

Special Considerations

• Roflumilast should be used with caution in underweight patients and those with depression, as recommended by the American Thoracic Society 1
• The European Respiratory Society recommends monitoring patients for adverse effects, particularly in the first few weeks of treatment with Roflumilast, and assessing exacerbation frequency 2
• The following guideline societies recommend roflumilast:

3, 2, 4, 5

• Roflumilast may be used in combination with long-acting muscarinic antagonists (LAMAs) and inhaled corticosteroids (ICS) 2, 5
• LAMAs are preferred over LABA monotherapy for exacerbation prevention in patients with COPD, as recommended by the European Respiratory Society 2

Limitations and Contraindications

• Roflumilast does not significantly improve quality of life as measured by St. George's Respiratory Questionnaire 2
• Roflumilast has not been shown to reduce overall mortality 2